Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic stage IV melanoma
dc.contributor.author | Diab, A | |
dc.contributor.author | Tykodi, S | |
dc.contributor.author | Curti, B | |
dc.contributor.author | Cho, D | |
dc.contributor.author | Wong, M | |
dc.contributor.author | Puzanov, I | |
dc.contributor.author | Lewis, K | |
dc.contributor.author | Maio, M | |
dc.contributor.author | Daniels, G | |
dc.contributor.author | Spira, A | |
dc.contributor.author | Tagliaferri, M | |
dc.contributor.author | Hannah, A | |
dc.contributor.author | Clemens, W | |
dc.contributor.author | Imperiale, M | |
dc.contributor.author | Bernatchez, C | |
dc.contributor.author | Haymaker, C | |
dc.contributor.author | Bentebibel, S | |
dc.contributor.author | Zalevsky, J | |
dc.contributor.author | Hoch, U | |
dc.contributor.author | Fanton, C | |
dc.contributor.author | Rizwan, A | |
dc.contributor.author | Aung, S | |
dc.contributor.author | Cattaruzza, F | |
dc.contributor.author | Iaccucci, E | |
dc.contributor.author | Sawka, D | |
dc.contributor.author | Bilen, M | |
dc.contributor.author | Lorigan, Paul C | |
dc.contributor.author | Grignani, G | |
dc.contributor.author | Larkin, J | |
dc.contributor.author | Jang, S | |
dc.contributor.author | Warzocha, E | |
dc.contributor.author | Sznol, M | |
dc.contributor.author | Hurwitz, M | |
dc.date.accessioned | 2019-03-04T12:32:46Z | |
dc.date.available | 2019-03-04T12:32:46Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Diab A, Tykodi S, Curti B, Cho D, Wong M, Puzanov I, et al. Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic stage IV melanoma. 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018); Nov 6; Washington, D.C., USA. 7-11 November 2018. J Immunother Cancer. 2018. p. 115. | en |
dc.identifier.doi | 10.1186/s40425-018-0423-x | en |
dc.identifier.uri | http://hdl.handle.net/10541/621584 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1186/s40425-018-0423-x | en |
dc.title | Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic stage IV melanoma | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Memorial Sloan Kettering Cancer Center, New York | en |
dc.identifier.journal | Journal for Immunotherapy of Cancer | en |
dc.description.note | en] |